---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-078162"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:24:04.194804+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx appoints Brendan Merrell COO; expands Stelmakh, Odence-Ford, D'Silva roles

## Summary
- Brendan Merrell named COO effective Aug 18, 2025; base salary $325k, target bonus 40%.
- Ed Stelmakh becomes Chief Financial & Strategic Officer, adding corporate strategy to finance duties.
- Marion Odence-Ford promoted to Chief Legal & Administrative Officer, adding admin oversight.
- Andy D'Silva promoted to Chief Business Officer, leading FP&A, IR, and strategic planning.
- Changes designed to accelerate Rule of 40 strategy (sustained growth + profitability) over 2-3 years.

## SEC filing metadata
- accession: 0001213900-25-078162
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390025078162/0001213900-25-078162-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390025078162/ea0253741-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-078162
- JSON: https://secwatch.observer/filing/0001213900-25-078162.json
- Plain text: https://secwatch.observer/filing/0001213900-25-078162.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.